Systematic Review and Stratified Meta-analysis of the Efficacy of Interleukin-1 Receptor Antagonist in Animal Models of Stroke

被引：90

作者：

Banwell, Victoria ^{[1
]}

Sena, Emily S. ^{[1
]}

Macleod, Malcolm R. ^{[1
]}

机构：

[1] Univ Edinburgh, Edinburgh EH4 2XU, Midlothian, Scotland

来源：

JOURNAL OF STROKE & CEREBROVASCULAR DISEASES | 2009年 / 18卷 / 04期

关键词：

Meta-analysis; systematic review; study quality bias; neuroprotection; publication bias; FOCAL CEREBRAL-ISCHEMIA; BRAIN-DAMAGE; RAT; OVEREXPRESSION; INJURY; MOUSE; EXPRESSION; VECTOR; BIAS;

D O I：

10.1016/j.jstrokecerebrovasdis.2008.11.009

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Background: Interleukin (IL)-1 receptor antagonist (RA) is an anti-inflammatory protein used to treat arthritis that has also been identified as a candidate stroke drug. Methods: We conducted a systematic review and meta-analysis of reports of the efficacy of IL-1 RA in animal models of focal cerebral ischemia. Results: We identified 16 published sources and one unpublished source of data. IL-1 RA reduced infarct volume by 38.2% (95%, confidence interval 31.2%-45.1%). Efficacy was higher with higher doses, earlier treatment, and central administration of drug. No studies used animals with hypertension or diabetes or tested efficacy beyond 3 hours. Conclusions: The animal data supporting IL-1 RA as a candidate drug for stroke are limited, and further experiments are required before proceeding to clinical trial.

引用

页码：269 / 276

页数：8

共 27 条

[1] ATTENUATION OF STROKE SIZE IN RATS USING AN ADENOVIRAL VECTOR TO INDUCE OVEREXPRESSION OF INTERLEUKIN-1 RECEPTOR ANTAGONIST IN BRAIN [J].

BETZ, AL ;

YANG, GY ;

DAVIDSON, BL .

JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 1995, 15 (04) :547-551

[2] Role of IL-1α and IL-1β in ischemic brain damage [J].

Boutin, H ;

LeFeuvre, RA ;

Horai, R ;

Asano, M ;

Iwakura, Y ;

Rothwell, NJ .

JOURNAL OF NEUROSCIENCE, 2001, 21 (15) :5528-5534

[3]

CLARK S, 2005, BRAIN 05 M INT SOC C

[4] Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate - Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial [J].

Cohen, S ;

Hurd, E ;

Cush, J ;

Schiff, M ;

Weinblatt, ME ;

Moreland, LW ;

Kremer, J ;

Bear, MB ;

Rich, WJ ;

McCabe, D .

ARTHRITIS AND RHEUMATISM, 2002, 46 (03) :614-624

[5]

Dinarello C A, 1998, Int Rev Immunol, V16, P457, DOI 10.3109/08830189809043005

[6] Bias in meta-analysis detected by a simple, graphical test [J].

Egger, M ;

Smith, GD ;

Schneider, M ;

Minder, C .

BMJ-BRITISH MEDICAL JOURNAL, 1997, 315 (7109) :629-634

[7] A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients [J].

Emsley, HCA ;

Smith, CJ ;

Georgiou, RF ;

Vail, A ;

Hopkins, SJ ;

Rothwell, NJ ;

Tyrrell, PJ .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2005, 76 (10) :1366-1372

[8] Recommendations for standards regarding preclinical neuroprotective and restorative drug development [J].

Feinklestein, SP ;

Fisher, M ;

Furland, AJ ;

Goldstein, LB ;

Gorelick, PB ;

Kaste, M ;

Lees, KR ;

Traystman, RJ ;

Albers, GW ;

Anwer, UE ;

Ashwood, T ;

Barone, FC ;

Basta, SL ;

Bogousslavsky, J ;

Buchan, AM ;

Cady, WJ ;

Chan, PH ;

Clemens, JA ;

Cox, BF ;

Craddock, RE ;

Cramer, SC ;

del Zoppo, GJ ;

Dielrich, WD ;

Elliott, P ;

Faden, AI ;

Feuerstein, GZ ;

Ginsberg, MD ;

Gold, M ;

Greene, WL ;

Hall, ED ;

Hsu, CY ;

Hunter, AJ ;

Lai, M ;

Lesko, LM ;

Levy, DE ;

Li, FH ;

Locke, KW ;

Lodge, D ;

Lowe, D ;

Marcoux, FW ;

McCulloch, J ;

McDermott, J ;

Meibach, R ;

Messersmith, EK ;

Moseley, M ;

Moskowitz, MA ;

Mueller, AL ;

Munro, F ;

Nudo, RJ ;

Oeda, J .

STROKE, 1999, 30 (12) :2752-2758

[9]

GARCIA JH, 1995, AM J PATHOL, V147, P1477

[10]

Hopkins Stephen J., 1995, Trends in Neurosciences, V18, P83, DOI 10.1016/0166-2236(95)93881-W

← 1 2 3 →